Research programme: tuberculosis immunotherapies - Transgene
Latest Information Update: 16 Jul 2016
At a glance
- Originator Transgene
- Class Bacterial proteins
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Tuberculosis in France (Parenteral)
- 26 May 2011 Early research in Tuberculosis in France (parenteral)